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Esterase mutation is a mechanism of resistance to
antimalarial compounds
Eva S. Istvan1,2, Jeremy P. Mallari1,2,w, Victoria C. Corey3, Neekesh V. Dharia3,w, Garland R. Marshall4,
Elizabeth A. Winzeler3 & Daniel E. Goldberg1,2
Pepstatin is a potent peptidyl inhibitor of various malarial aspartic proteases, and also has
parasiticidal activity. Activity of pepstatin against cultured Plasmodium falciparum is highly
variable depending on the commercial source. Here we identify a minor contaminant
(pepstatin butyl ester) as the active anti-parasitic principle. We synthesize a series of
derivatives and characterize an analogue (pepstatin hexyl ester) with low nanomolar activity.
By selecting resistant parasite mutants, we ﬁnd that a parasite esterase, PfPARE (P. falciparum
Prodrug Activation and Resistance Esterase) is required for activation of esteriﬁed pepstatin.
Parasites with esterase mutations are resistant to pepstatin esters and to an open source
antimalarial compound, MMV011438. Recombinant PfPARE hydrolyses pepstatin esters and
de-esteriﬁes MMV011438. We conclude that (1) pepstatin is a potent but poorly bioavailable
antimalarial; (2) PfPARE is a functional esterase that is capable of activating prodrugs;
(3) Mutations in PfPARE constitute a mechanism of antimalarial resistance.
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R
esistance to antimalarial drugs is hampering efforts in
disease management. The recent emergence of tolerance/
resistance to the artemesinins has given rise to the spectre
of failure of artemesinin combination therapies, the mainstay of
control regimens1. Indeed, resistance has developed to virtually
all drugs used for malaria. Resistance mechanisms include efﬂux
pump gene mutation and copy number variation (Mdr1, Crt,
Mrp1), enzyme active site mutation (DHFR, DHPS, SoxP, CytC)
and Naþ /Hþ exchanger gene mutation (ATP4) (refs 2,3).
There is a pressing need for new antimalarials and for a better
understanding of extant and potential resistance mechanisms.
Pepstatin is a natural product isolated nearly 50 years ago from
Streptomyces argenteolus and related actinomycetes4. It is a well-
characterized aspartic protease inhibitor and derivatives of this
scaffold are in clinical use as antiretroviral therapies. Pepstatin
has been shown to kill malaria parasites in culture and to cure
infection in a rodent malaria model5–7. However, the activity of
pepstatin against cultured Plasmodium falciparum is highly
variable depending on the commercial source8,9.
In this study, we fractionated an active commercial preparation
of microbial pepstatin and identiﬁed a small contaminant as the
active principle, pepstatin butyl ester. By selecting parasite
mutants resistant to pepstatin esters, we found that a parasite
alpha/beta hydrolase, PfPARE (P. falciparum Prodrug Activation
and Resistance Esterase), is required for activation of the
esteriﬁed compound. Esterase mutation is a new mechanism of
antimalarial resistance.
Results
Isolation and characterization of potent pepstatin analogues.
We used LC/MS to fractionate and characterize the components
of a potent pepstatin batch (Fig. 1a). Fractions were tested for
antimalarial activity. The dominant peak eluted at 4.5min and
had a mass of 686.47, corresponding to pepstatin. Pure pepstatin
was inactive against cultured P. falciparum (Fig. 1e). One minor
component (B5% of the total chromatographic signal) that
eluted later in the gradient was highly active. Mass spectrometric
analysis indicated an m/z of 742.53 for the molecule in the active
fraction. Tandem mass spectrometry showed a peptide-like
fragmentation that closely resembled pepstatin; however, an extra
mass of 56.06, corresponding to a butyl group, was present on the
C-terminal statine residue (Fig. 1b–d). We synthesized pepstatin
n-butyl ester (PBE) and determined that it is three orders of
magnitude more potent than unmodiﬁed pepstatin (Fig. 1e).
We tested a series of PBE analogues (Table 1) to probe the
structural basis for antimalarial activity. All pepstatin esters were
signiﬁcantly more active than pepstatin, with pepstatin n-hexyl
ester (PHE) being the most potent (EC50¼ 25 nM). Penetratin
peptide-derivatized pepstatin, as well as pepstatin n-butyl
amide, however, were poorly active on blood-stage parasites.
N-terminally acetylated pepstatin was also inactive. Our results
indicate that esteriﬁcation at the C-terminus of pepstatin is
critical for compound activity and that increasing the length of
the ester alkyl chain increases antimalarial potency (hexyl4butyl
 ethyl  methyl).
Selection of pepstatin ester-resistant parasites. Selection of
mutants resistant to compounds is a powerful way to determine
antimalarial mode of action10,11. We raised pepstatin ester-
resistant parasites by treating 4 107 3D7 parasites with PBE in a
single-step selection. Compound treatment initially cleared
cultures of visible parasites and surviving parasites multiplied
to detectable levels by 2–3 weeks. Multiple selections yielded
viable parasites. Resistant parasites were recloned and tested
for sensitivity to pepstatin ester. Selections from different
concentrations of PBE were all similarly highly resistant to
pepstatin ester. Four clones were analysed by full-genome
sequencing (Table 2). Each had a non-synonymous coding
mutation in the same gene, PF3D7_0709700 (pfpare). Sequencing
of the putative polymorphism-containing gene in other
PBE-resistant clones selected from a different parasite strain,
HB3, revealed four additional mutations (Supplementary
Table 1). Seven of the eight mutations we isolated are missense
and one results in an early stop.
Conﬁrmation of the role of PfPARE mutations in resistance.
We recombinantly modiﬁed the parasites in a clean genetic
background to conﬁrm that the mutations isolated in resistant
parasites provided resistance to pepstatin esters. One of the
C-terminal mutations (L357P) was introduced into parasites by
single-crossover allelic exchange. Concurrently, we generated
recombinants preserving the wild-type sequence. Introduced
wild-type or mutant protein is expressed from the endogenous
promoter and contains a C-terminal GFP, while the original
genomic version is promoterless. Correct integration in clonal
parasite lines was conﬁrmed by sequencing of PCR products from
integrated plasmids and by Southern blot (Supplementary Fig. 1).
GFP-expressing, wild-type parasites were similarly sensitive
to PHE compared to the un-transfected, parental parasites,
while L357P-expressing parasites were highly resistant to the
compound (Fig. 2a).
Live microscopy showed diffuse cytoplasmic GFP ﬂuorescence
(Fig. 2b). The intensity of the GFP ﬂuorescence was weak in ring
stages and increased with parasite maturity. Western blots of
parasite extracts conﬁrmed expression of intact GFP fusion
proteins (Fig. 2c). Compared to the wild-type GFP-tagged
parasites, the GFP band in the L357P PfPARE parasite extracts
was consistently weaker (Fig. 2c).
PfPARE has sequence similarity to alpha/beta hydrolases.
PfPARE is annotated as a lysophospholipase and is homologous
to putative plant lysophospholipases. Structure prediction
(Fig. 2d) supports the notion that the esterase belongs to the
family of alpha/beta hydrolases, which are enzymes with very
diverse speciﬁcities. Carboxylic acid esters, epoxides, lipids and
phospholipids are substrates of this enzyme class. The gene is
present on chromosome seven and not close to the telomeres.
However, it belongs to a conserved gene family in Plasmodium
known as PST-A, many of whose members are subtelomeric12. At
least three other genes predicted to encode hydrolases closely
related to pfpare are present in P. falciparum: PF3D7_1252600
(54% identical over 349 residues); PF3D7_1401500 (55% identical
over 350 residues) and PF3D7_1038900 (53% identical over 338
residues). These three homologous hydrolases contain key
catalytic residues and likely encode active enzymes.
Three putative catalytic residues in PfPARE are readily
identiﬁable (S179, D308 and H338). S179 resides in the highly
conserved pentapeptide G-x-S-x-G, also known as the ‘nucleo-
phile elbow’13. As in other hydrolases, the core of the alpha/beta
fold accommodates less conserved insertions that dictate
substrate speciﬁcity14. Inspection of the structural model in
Fig. 2d suggested that some of the resistance-conferring
mutations we had obtained likely abolish enzymatic activity.
The mutation M180K (clone HB3-R4) resides adjacent to the
putative catalytic serine, while in clone 3D7-R4 the predicted
protein is truncated and three key catalytic residues (S179, D308
and H338) are missing. Five different mutations cluster in the
C-terminal region of the esterase, which is predicted to adopt an
alpha-helical conformation. This part of the protein participates
in homo-dimer formation in related hydrolases and may stabilize
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the enzymes14. We observed low GFP ﬂuorescence and decreased
signal on western blots from parasite extracts containing the
L357P resistance-conferring mutation. Possibly, the enzyme fold
is destabilized by a proline-induced break in the C-terminal helix.
Alternatively, the change of leucine to proline may slow the
folding kinetics of PfPARE, as prolyl cis/trans isomerizations are
frequently rate-limiting steps in protein folding15.
PfPARE is an active esterase. To test whether PfPARE activity is
important for parasite viability or resistance to pepstatin esters,
we generated a parasite clone in which we mutated a predicted
key catalytic residue (S179T). The S179T mutation resulted in
PHE resistance (Fig. 2a). Active site mutant parasites were also
resistant to other pepstatin esters (Supplementary Table 2).
Growth rates were unaffected by either L357P or S179T muta-
tions, indicating that catalytic activity is dispensable for asexual
malaria parasites (Supplementary Fig. 2). We assessed whether
PfPARE had esterase activity by generating wild-type and active
site mutant proteins in E. coli. We initially attempted to express
the same active site mutant that we had used in the parasite
(S179T). However, S179T expressed at low levels, was unstable
and could not be puriﬁed. We did succeed in expressing another
active site mutant (S179G), and this protein was used in
subsequent studies. Afﬁnity puriﬁed proteins were incubated with
the generic esterase substrate p-nitrophenyl butyrate (PNPB), and



































































































































































Figure 1 | Potent pepstatin preparations contain pepstatin esters. (a) Separation of older, potent pepstatin by C18 reverse phase chromatography. The
prominent peak eluting at 4.5min has a mass of 686.47 and does not kill malaria cultures at 40mM. The minor peak eluting at 6.4min has a mass of
742.53 and is highly potent. (b,c) MS/MS fragmentation of the 686.47 mass peak (b) and the 742.53 mass peak (c). Mass-to-charge ratios (m/z) of
selected fragments are indicated in black numbers. The blue letters and red numbers match fragments of the structure key in (d). (d) Structure and MS
fragmentation key of pepstatin or pepstatin ester. Blue lines and letters mark N-terminal fragments present in the free acid or ester of pepstatin. Red lines
and numbers show C-terminal fragments which have an additional 56 amu in the pepstatin ester. (Note that there is loss of a proton on pepstatin upon the
addition of the C4H9 ester). (e) Concentration responses of blood-stage 3D7 parasites (all in 0.1% DMSO) with pepstatin (black) or two syntheses of
pepstatin n-butyl ester (PBE) (red, blue) measured using a ﬂow cytometry-based assay. PBE inhibition data were ﬁt to a sigmoidal growth inhibition curve.
Error bars show s.d.±indicates standard errors calculated for the biological triplicates of the experiment shown. N¼4.
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photometrically. Wild-type PfPARE was catalytically active, while
the S179G mutant protein activity was near background levels
(Fig. 2e).
Esteriﬁed pepstatin is taken up by cells and processed. We
performed in-cell metabolism experiments to determine the fate
of pepstatin and its ester analogues in parasitized RBCs. Pepstatin
or pepstatin esters were incubated with mature ring-stage parasite
cultures for 5–6 h. Samples from HPLC-fractionated extracts were
analysed by mass spectrometry. Cellular uptake of pepstatin esters
and their conversion to free pepstatin could readily be detected in
parasite extracts (Fig. 3a). In contrast, cellular accumulation of
exogenously added free pepstatin was undetectable. These data
suggest that the ionizable carboxylic acid moiety of pepstatin
decreases cellular penetration, resulting in poor parasiticidal
activity. Replacing the carboxylic acid with an ester results
in a neutral molecule, likely resulting in the greatly improved
intracellular accumulation and antimalarial potency seen.
After the uptake of pepstatin esters into parental parasites,
conversion to free pepstatin was easily detected (Fig. 3b). In
contrast, only the pepstatin ester starting material was observed
when we used the S179T mutant parasite, indicating that
compound processing, but not uptake, was affected by the
mutation (Fig. 3c,d). We postulated that PfPARE can act directly
on the compounds and tested whether recombinant proteins
could hydrolyse pepstatin esters. Afﬁnity-puriﬁed wild-type or
S179G mutant proteins were incubated with PHE or PME and
analysed by LC/MS. Detectable amounts of pepstatin were
generated when wild-type protein was incubated with PHE, but
no pepstatin was detected when we instead used the S179G
mutant protein (Fig. 3e). Interestingly, only a trace amount of
pepstatin was detected when the compound was PME rather than
PHE. Previously, we had found PME to be much less potent in
parasites than PHE (Table 1). Low potency of short esters could
be due to poor penetration or poor activity. The low activity of
the recombinant enzyme on PME suggests that esterase activity in
the parasite determines efﬁcacy of pepstatin esters.
PfPARE is active on another antimalarial ester scaffold. We
were curious whether PfPARE could act on ester-containing
antimalarials other than pepstatin esters and performed
concentration-response experiments with three open source
antimalarial compounds. MMV011438, a benzodiazepine,
showed differential sensitivity in wild-type and mutant (L357P or
S179T) esterase-expressing parasites described above (Fig. 4a),
while two other compounds were equipotent (Fig. 4b,c).
Incubation of the three compounds with recombinant enzyme
revealed hydrolysis of MMV011438 but no modiﬁcation of the
other two compounds (Fig. 3e). MMV030666 and MMV021735
are likely unaffected by activity of PfPARE in the parasite because
they are poor substrates. Inactivity on these two compounds is
not surprising, as MMV030666 is a tertiary carbamate and
MMV021735 is a sterically hindered ester. We raised parasites
resistant to MMV011438 as part of the MDTIP consortium16.
Whole genome sequencing revealed that each evolved clone bore
a missense mutation in pfpare (Table 2). These data indicate that
Table 1 | Structures and in vitro activities of pepstatin and analogues.
Compound Structure Potency* (lM)
Pepstatin (P) Iva-Val-Val-Sta-Ala-Sta-OH none at 40
Acetyl pepstatin Ac-Val-Val-Sta-Ala-Sta-OH none at 20
Pepstatin-Penetratin Pepstatin-RQIKIWFQNRRMKWKK-OH none at 1
Pepstatin n-butyl amide Pepstatin-CO-NH-(CH2)3CH3 none at 20
Pepstatin methyl ester (PME) Pepstatin-COO-CH3 5.12±0.15
Pepstatin ethyl ester (PEE) Pepstatin-COO-CH2-CH3 0.730±0.012
Pepstatin 3-methyl-1-butyl ester (PMBE) Pepstatin-COO-(CH2)2CH-(CH3)2 0.071±0.010
Pepstatin n-butyl ester (PBE) prep 1 Pepstatin-COO-(CH2)3-CH3 0.083±0.006
Pepstatin n-butyl ester (PBE) prep 2 Pepstatin-COO-(CH2)3-CH3 0.092±0.006
Pepstatin n-hexyl ester (PHE) prep 1 Pepstatin-COO-(CH2)5-CH3 0.019±0.003
Pepstatin n-hexyl ester (PHE) prep 2 Pepstatin-COO-(CH2)5-CH3 0.026±0.003
EC50s of pepstatin and analogues against 3D7 asexual stage parasites measured using a ﬂow cytometry-based assay. Inhibition data were ﬁt to a sigmoidal concentration-response curve using the least
squares ﬁt function and without outlier elimination±are standard errors. n¼ 2–5 (biological replicates performed in triplicate for each experiment).
*Potency—where appropriate, potency is presented as EC50. For inactive compounds, inhibition at highest concentration is presented.





Chr Position Gene name Gene description Effect Impact Amino
acid
3D7-R1 PBE 3 1066792 Intergenic
5 1290269 PF3D7_0531600 18S ribosomal RNA Ribosomal RNA
7 435126 PF3D7_0709700 Putative esterase Non synonymous coding Mis-sense L357P
3D7-R2 PBE 4 276762 PF3D7_0405100 Sec24 subunit b Synonymous coding Silent S21
4 283984 PF3D7_0405300 Sequestrin Synonymous coding Silent V1438
7 435228 PF3D7_0709700 Putative esterase Non synonymous coding Mis-sense L323H
3D7-R3 PBE 3 1066792 Intergenic
7 435781 PF3D7_0709700 Putative esterase Stop gained Non-sense Q139Stop
3D7-R4 PBE 6 566727 PF3D7_0613800 Transcription factor (AP2) Non synonymous coding Mis-sense Q197E
7 435138 PF3D7_0709700 Putative esterase Frame Shift Truncation
Dd2-2G1 MMV011438 5 992699 Intergenic
7 435160 PF3D7_0709700 Putative esterase Non-synonymous coding Mis-sense N346Y
Whole genome sequencing from gDNA of compound resistant clones reveals SNPs in PF3D7_0709700. PCR sequencing of PF3D7_0709700 in additional MMV011438 resistant clones indicated that
they either had the same mutation as clone 2G1 or a missense (T to G) at bp 435138, resulting in I353S. Filter parameters used to analyse data are in Supplementary Table 3.
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PfPARE is an active esterase with moderate substrate speciﬁcity
that hydrolyses ester-containing prodrugs.
Discussion
We have clariﬁed the differences in potency of different pepstatin
preparations reported previously and found that antimalarial
activity is due not to pepstatin, but to low levels of a highly potent
pepstatin ester. It is unclear whether active microbial pepstatin
preparations contain pepstatin ester because it is produced
by Actinomycetes or because pepstatin was modiﬁed during
compound isolation. We found that esteriﬁcation is required for
parasite uptake of pepstatin, and in this work, we synthesized a
series of pepstatin esters, identiﬁed structural features important
for activity, and developed a potent inhibitor with low nanomolar
EC50 against cultured P. falciparum. Clearly, pepstatin esters are
not good lead compounds for drug discovery as resistance arose
quickly. Nevertheless, we have gained valuable information:
(1) pepstatin likely inhibits the activity of an essential aspartic
protease; and (2) the free carboxylic acid moiety is crucial for
pepstatin’s potency. These ﬁndings may help in the development of
new antimalarials that do not require esteriﬁcation for cell uptake.
PfPARE is expressed during the asexual blood stages and
resides in the parasite cytoplasm where it may encounter drugs or
substrates. Its function is dispensable in blood-stage parasites.
The physiological substrate of PfPARE is unknown. Parasites
quickly developed resistance to pepstatin esters and to
MMV011438 by inactivating the esterase. Given the broad
substrate speciﬁcity of this enzyme it is likely that PfPARE can
hydrolyse a range of other ester-containing antimalarial com-
pounds and that mutations in PfPARE can provide resistance to
new potential drugs. It is possible that PfPARE is not essential
because other hydrolases are capable of compensating for its
physiological function when the esterase is mutated. It is very
interesting that these other esterases cannot activate pepstatin
esters in the absence of PfPARE. A detailed comparison of
substrate speciﬁcities would be worthwhile.
To the known antimalarial resistance mechanisms a new one
can be added: loss-of-function mutation of a prodrug convertase.
There are now thousands of antimalarial hits from whole parasite
compound screens. A survey of 125 compounds with antimalarial
activity from the pathogen box and 400 compounds from the




































































Figure 2 | Mutations in the esterase PfPARE are responsible for resistance to pepstatin esters. (a) Concentration-responses of parental parasites
(black), wild-type allelic replacement (blue), L357P allelic replacement (green) or active-site S179Tallelic replacement (orange) to PHE. EC50 values were
measured with a ﬂow cytometry-based assay. Inhibition data (parent, wild-type) were ﬁt to a sigmoidal concentration-response curve. Error bars show s.d.
± indicates standard errors calculated for the biological triplicates of the experiment shown. N¼ 2. (b) PfPARE is expressed in asexual parasites. Live
ﬂuorescence microscopy with GFP-tagged PfPARE shows the protein is in the cytoplasm. Scale bar 5 mm. (c) Western blot of wild-type, L357P or S179T
GFP-tagged PfPARE using an a-GFP antibody. The protein is expressed from the endogenous promoter. The predicted MW of the PfPARE-GFP fusion is
69 kDa. HAD1 (33 kDa) is a loading control. (d) Structural model of PfPARE generated by the Robetta Protein Structure Prediction Server. The gradual
colour changes (from blue N-terminus to red) trace the sequence. The side-chains of the three catalytic residues (S179, D308, H338) are drawn as red
sticks. Residues mutated in resistant parasites are in grey. (e) Recombinant PfPARE has esterase activity on p-nitrophenyl butyrate (PNPB) (black). Puriﬁed
protein (0.27mg) was incubated with increasing PNPB and formation of the product p-nitrophenol (PNP) was monitored at 400nm. Amount of PNP
generated as a function of PNPB concentration were ﬁt to a Michaelis-Menten equation. Activity of wild-type protein (black) is signiﬁcantly different from
S179G mutant protein (red) (F-test; Po0.05). Error bars show s.d.
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the possibility that some are prodrugs subject to rapid resistance
development. Testing against parasites with an inactivated
esterase gene provides a facile screen to identify such
compounds. A limitation of our study is that other non-
essential esterases may be active on different compounds.
Furthermore, we did not gain full understanding of the
substrate speciﬁcity of PfPARE.
Resistance to prodrug activation has precedence in the
antimicrobial literature. Acyclovir is an anti-herpesvirus nucleo-
side analogue that is activated by a viral kinase. Since this
thymidine kinase is not essential to the virus, inactivation or
deletion leads to acyclovir resistance18. Isoniazid is a prodrug for
tuberculosis that must be activated by the bacterial KatG catalase.
Mutations in KatG prevent activation19. Metronidazole is a
drug that needs to be reduced by the bacterial NADPH-
dependent enzyme RDXA for activity against Helicobacter20.
Microaerophilic protists such as Entameba histolytica have
similar genes, but resistance to metronidazole is achieved by
different mechanisms21. Esterase inactivation, then, is the ﬁrst
example of a parasitic mechanism to avoid killing by failure to
activate a prodrug. Prodrug synthesis is an attractive way to move
compounds into cells, but in Plasmodium, resistance is potentially
a major liability.
Methods
Fractionation of potent pepstatin. Fractionation of microbial pepstatin
(Sigma Aldrich, a gift from Hagai Ginsburg, Jerusalem, Israel) was performed on a
reverse-phase C18 column using a 0-50% gradient of acetonitrile/H20 with 0.1%
formic acid. Fractions were analysed with MS/MS on a hybrid FTMS consisting of
a Thermo LTQ-FT and a Thermo Orbitrap.
Synthesis of pepstatin analogues. Acetyl pepstatin, pepstatin methyl ester and
pepstatin-penetratin were purchased from Calbiochem. Ethanol, 1-butanol,
3-methyl-1-butanol and 1-hexanol were purchased from Sigma-Aldrich. Esters
were synthesized according to the esteriﬁcation method of Wilcox22. Brieﬂy,
pepstatin (synthetic, Calbiochem) (10mg, 15 mmol) was dissolved in the
appropriate alcohol (8 g, 80mmol) and 1N HCl was added to a concentration of
0.1 N (1mmol). Reactions were stirred at room temperature for 7–10 days and
evaporated under argon. Crude products were dissolved in dimethylsulphoxide and
puriﬁed by C18 chromatography. Inhibitor concentrations were determined by
preparing a standard curve of absorption (218 nm) for pepstatin and calculating the
areas under the curve for the pepstatin derivatives. Structures were conﬁrmed by
mass spectrometry (measured masses of Na-adducts of PEE¼ 738.3; PBE¼ 763.4;
PMBE¼ 780.0; PHE¼ 793.6). MALDI-TOF spectra of PEE, PBE, PMBE, PHE and
pepstatin n-butyl amide are in Supplementary Fig. 3. 1HNMR and 13CNMR peak
assignments for PHE are in the Supplementary Note 1. Pepstatin n-butyl amide
was synthesized by dissolving 13.5 mmol pepstatin, 27mmol HBTU and 27 mmol
HOBt in a solution of dichloromethane (1ml) and dimethylformamide (0.5ml).
Three equivalents of n-butylamine was added in DIEA and the reaction was
stirred at room temperature for 18 h. The product was puriﬁed on HPLC and
characterized by MALDI-TOF (mass of 765.2, corresponding to the Na-adduct of
the amide) (Supplementary Fig. 3).
Parasite culture. 3D7, mycoplasma free, was a gift from P.K. Rathod (University
of Washington). The identity of the strain was conﬁrmed by whole-genome
sequencing. HB3 was obtained from the MR4 repository at ATCC (Cat. No. MRA-
155). Parasites were cultured in human red blood cells (de-identiﬁed donors from
the St Louis Children’s Hospital blood bank) at 2% hematocrit in RPMI 1640 with
0.25% (w/v) Albumax23,24. Resistance selections were performed with 4 107 3D7
or HB3 parasites in a single-step with either 280 nM or 1.2 mM PBE. Resistant
parasites were cloned by limiting dilution and two clones for each mutant were
analysed. Concentration-response experiments were done in biological triplicates
with synchronous, young ring-stage cultures (1–1.2% starting parasitemia) and at
least two times. Parasitemias (percentage of total erythrocytes infected with
parasites) were measured approximately 70–80 h post compound addition by
nucleic acid staining of iRBCs with 0.8 mgml 1 acridine orange in PBS. Growth
P
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Figure 3 | In cell metabolism of pepstatin esters. (a) Detection of
pepstatin (P) or pepstatin esters (E) by MALDI-TOF. Fractions of 3D7
lysates after incubation with pepstatin (P) or analogues were spotted onto a
MALDI plate and scored for the presence or absence of compounds with
appropriate mass. This MS assay is not quantitative. (b–d) MALDI-TOF
spectra of HPLC fractions (C18) from whole cells extracts of 3D7 (b) or
S179T mutant parasite (c,d) infected RBCs, incubated with PBE. The
dominant peak of 707.0 (b) corresponds to the Na-adduct of pepstatin. The
dominant peak of 766.1 (c) corresponds to the Na adduct of PBE. Pepstatin
was never detected in any fractions prepared from S179T mutant parasite
extracts (d). (e) Activity of recombinant PfPARE on pepstatin esters and
MDTIP compounds16. Wild-type or mutant proteins were incubated with
compounds and amounts of de-esteriﬁed products were determined by LC/
MS (triplicate reactions). Results for incubations with wild-type enzyme are
in black, with S179G mutant enzyme is in red. *Pepstatin from incubations
with PM could be detected by MALDI-TOF, but not signiﬁcantly by LC/MS.
Error bars are s.d.
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was normalized to parasite cultures with carrier only (dimethylsulphoxide) and
chloroquine was used as a 0% growth control. For compounds and strains where
inhibition was observed, data were ﬁt to a sigmoidal growth inhibition curve. No
curve ﬁtting was performed for resistant parasite clones or inactive compounds.
Growth curves for wild-type and mutant pfpare parasites were done twice with
asynchronous parasite cultures in biological triplicate by measuring daily
parasitemias. Data were ﬁt to an exponential growth equation. GraphPad Prism 5.0
was used for data analysis using the least square ﬁt function without outlier
elimination and without constraints. Where appropriate, P values (extra sum-of-
squares F test) were calculated to evaluate signiﬁcant differences between samples.
Error bars indicate s.d. Concentration-responses of Wt and S179T expressing
parasite clones with well-characterized antimalarials are reported in Supplementary
Fig. 4. Stage speciﬁcity of pepstatin esters was investigated with a PBE washout
experiment (Supplementary Fig. 5).
Genetic modiﬁcation and analysis. Allelic exchange constructs were based on the
pPM2GT vector24. The ORF of PF3D7_0709700 was cloned into the AvrII/XhoI
sites using primers (forward¼ 50-CTCGAGATGAAGAGCCAGGGTGGAGGG-30
and reverse¼ 50-CCTAGGTACTTGTTCTTCTTGTTTGGG-30). Using this
strategy pfpare is expressed from the endogenous promoter in-frame with a
C-terminal GFP (the native stop is deleted). The mutant constructs were prepared
using QuikChange Mutagenesis. The L357P mutagenesis used the primer (50-GGA
ACCTGGAAATGAAAGAGTTTTAAAAAAAATTATCACATGGCC-30 ; bold
letters indicate bp change). This mutant construct contains a synonymous
substitution that removes a NheI restriction site at bp 1044. The S179T
mutagenesis used the primer (50-CCATTTTATATTATGGGATTAACCATGGG
AGGTAATGTTGTTTTAAGAACTTTAC-30). This mutant construct introduces
an NcoI site at bp 537. Transfections were performed in duplicate using 100 mg of
supercoiled DNA with 3D7 ring-stage parasites. WR99210 (5 nM) was added to
mature ring-stage parasites one cycle after transfection and used to select resistant
parasites. Transfectants were cloned by limited dilution. To conﬁrm correct
integration, we used the AlkPhos Direct Kit for Southern blots as described (Fisher
Scientiﬁc)24. PCR products for the Southern blots were generated with the
following primer pairs (Supplementary Fig. S1A: 50-GTATAAAATCATATACTA
TATCATC-30 and 50-CATATATTTCCATATTCCCATTTTC-30 ; Supplementary
Fig. S1C: 50-CTATCACTTCTAACTATATATGTAAC-30 and 50-CCATTAGCTA
AATTCTTAGGAAGC-30).
Fluorescence microscopy and western blotting. Fluorescence microscopy was
performed on live, GFP-expressing parasites using a Zeiss Axioskope. Nucleic acid
was detected by staining with DAPI. For western blotting, 3 108 parasites were
released from iRBCs with 0.035% saponin and lysed in Ripa buffer. For each
sample, 9 107 parasites were loaded onto a 12% TGX gel (BioRad). Proteins were
transferred onto PVDF using wet transfer with 20% methanol. Blots were blocked
overnight at 4 C with Licor Odyssey block buffer. Primary antibodies were
LivingColors mouse-a-GFP (Takara, Cat. No. 632380) (1:500) and rabbit-a-HAD1
(1:1,000) (a gift from Dr Audrey R. Odom, Washington University25). Secondary
antibodies were goat-a-mouse (800) and donkey-a-rabbit (680) IR-Dyes (1:20,000)
from Licor.
Expression of recombinant PfPARE. A codon-optimized version (most
abundant codon for E. coli) of the PF3D7_0709700 gene was purchased from
IDT (Supplementary Note 2). The gene product lacked an amino terminal low
complexity region that is predicted to be disordered (amino acids 1–22). After
cloning into the expression vector pET15-b using the XhoI restriction site, the
protein contains an N-terminal hexa-His tag. Including the His-tag and amino
acids generated from the vector sequence, the MW of the recombinant enzyme is
42,700. The S179G mutation was introduced using QuikChange Mutagenesis
(Agilent) with the primer (50-CTGCCGTTTTACATTATGGGTCTGGGTATG
GGTGGCAACGTTGTGCTGC-30). Proteins were expressed in C41(DE3) cells
(Lucigen; Cat. No. 60442) at 37 C with 100 mM IPTG for 5 h. Proteins were
puriﬁed on high-density Ni-resin (Goldbio) in NaPO4 buffer (20mM, pH 7.2, with
150mM NaCl). We attempted to use the active site mutant S179T that we had
studied in parasite clones as a less-active protein control. However, recombinant
expression of S179T esterase only yielded inclusion bodies that could not be
successfully refolded. Instead, we generated soluble recombinant protein with
the S179G mutation. For assays with p-nitrophenol butyrate (PNPB), 0.27 mg of
puriﬁed protein was incubated with 0 to 833 mM PNPB (prepared as a 50mM stock
in acetonitrile) in PBS for 5min at 22 C. Reactions were stopped by the addition of
100 ml acetonitrile and formation of the yellow hydrolysis product p-nitrophenol
(PNP) was monitored at 400 nm. For assays analysed by LC-MS, 35 mg of
either wild-type or S179G protein was incubated for 3 h at 22 C with 5 nmol of
compound. The reactions were analysed with a Thermo Scientiﬁc TSQ Vantage

































































Figure 4 | PfPARE hydrolyzes and activates an ester-containing prodrug. Concentration-responses against 3D7 asexual parasites (right) and structures
(left) of compounds from the MDTIP consortium16. EC50 values were measured with a ﬂow cytometry-based assay. Parasite strains are labelled black
(3D7), blue (pfpare wild-type allelic exchange), green (pfpare L357P allelic exchange) and orange (pfpare S179Tallelic exchange). Inhibition data were ﬁt to
a sigmoidal concentration-response curve. (a) MMV011438, (b) MMV021735, (c) MMV030666. In a, F-test; Po0.0001 for S179Tor L357P compared to
Wt. Error bars show s.d.±indicates standard errors calculated for the biological triplicates of the experiment shown. N¼ 2.
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In-cell metabolism of pepstatin esters. A volume of 150–240ml of mid-ring
parasite cultures at 10–20% parasitemia was incubated with 2 mM compound for
5–6 h. In experiments where comparisons between parasite cultures were impor-
tant (that is, wild-type and mutant esterase parasite clones), culture amounts and %
parasitemia were matched. Compounds not taken up by parasites were removed by
permeabilizing infected RBCs with 0.035% saponin and parasites pellets were
washed three times with cold PBS. After freeze-thawing, pellets were resuspended
in cold 20mM NaPO4, pH 7.2 (350 ml of buffer per ml of infected culture),
slowly mixed at 4 C for 3 h and extracted with 3 volumes of cold acetonitrile.
Centrifugation supernatants (15min, 2,100g) of the extractions were loaded onto a
reverse-phase C18 column equilibrated in H2O with 0.1% formic acid and eluted
with a linear gradient (solvent B¼ 100% acetonitrile with 0.1% formic acid).
Fractions were collected, mixed 1:1 with a-cyano-4-hydrocinnamic acid, spotted
onto a sample plate and analysed on a Voyager 4254 MALDI-TOF.
Full genome sequencing. For sequencing, DNA libraries for each gDNA sample
were prepped with the Nextera XT kit (Cat. No. FC-131-1024, Illumina), using the
dual index protocol. Libraries were clustered using the RapidRun mode on the
Illumina HiSeq 2500, and 100 base pairs were sequenced on either fragment end for
each sample. Paired-end reads were aligned to the P. falciparum 3D7 reference
genome (PlasmoDB v. 26.0), as described previously26 with the exception that
mutations were called using GATK’s HaplotypeCaller instead of UniﬁedGenotyper.
Mutations, including single nucleotide polymorphisms and insertion/deletions
(INDELS), were ﬁltered based on general recommendations from GATK
(Supplementary Table 3). Additional ﬁlters were applied post HaplotypeCaller,
which included removing positions where read coverage was o5 in the parent and
any position where all samples had a heterozygous ratio40.2 (reference/total reads).
Data availability. Sequence data have been deposited in the National Center for
Biotechnology Information (NCBI) Sequence Read Archive database with acces-
sion code SRP077277. Coordinates of the PfPARE model generated by the Robetta
Structure Prediction Server are available on modelarchive.org with DOI (10.5452/
ma-aqqwe). All other relevant data are available from the authors on request.
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